Literature DB >> 23835712

Challenges of guarantee-time bias.

Anita Giobbie-Hurder1, Richard D Gelber, Meredith M Regan.   

Abstract

The potential for guarantee-time bias (GTB), also known as immortal time bias, exists whenever an analysis that is timed from enrollment or random assignment, such as disease-free or overall survival, is compared across groups defined by a classifying event occurring sometime during follow-up. The types of events associated with GTB are varied and may include the occurrence of objective disease response, onset of toxicity, or seroconversion. However, comparative analyses using these types of events as predictors are different from analyses using baseline characteristics that are specified completely before the occurrence of any outcome event. Recognizing the potential for GTB is not always straightforward, and it can be challenging to know when GTB is influencing the results of an analysis. This article defines GTB, provides examples of GTB from several published articles, and discusses three analytic techniques that can be used to remove the bias: conditional landmark analysis, extended Cox model, and inverse probability weighting. The strengths and limitations of each technique are presented. As an example, we explore the effect of bisphosphonate use on disease-free survival (DFS) using data from the BIG (Breast International Group) 1-98 randomized clinical trial. An analysis using a naive approach showed substantial benefit for patients who received bisphosphonate therapy. In contrast, analyses using the three methods known to remove GTB showed no statistical evidence of a reduction in risk of a DFS event with bisphosphonate therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23835712      PMCID: PMC3732313          DOI: 10.1200/JCO.2013.49.5283

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  19 in total

Review 1.  Immortal time bias in pharmaco-epidemiology.

Authors:  Samy Suissa
Journal:  Am J Epidemiol       Date:  2007-12-03       Impact factor: 4.897

2.  Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases.

Authors:  Lesley H Curtis; Bradley G Hammill; Eric L Eisenstein; Judith M Kramer; Kevin J Anstrom
Journal:  Med Care       Date:  2007-10       Impact factor: 2.983

3.  Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables.

Authors:  James R Anderson; Kevin C Cain; Richard D Gelber
Journal:  J Clin Oncol       Date:  2008-08-20       Impact factor: 44.544

4.  Marginal Mean Models for Dynamic Regimes.

Authors:  S A Murphy; M J van der Laan; J M Robins
Journal:  J Am Stat Assoc       Date:  2001-12-01       Impact factor: 5.033

5.  Biased hormonal therapy duration analysis makes results uninterpretable.

Authors:  Catherine M Tangen; Bryan H Goldman; Gregory P Swanson; Ian M Thompson
Journal:  J Clin Oncol       Date:  2009-09-28       Impact factor: 44.544

6.  Does cardiac transplantation prolong life? A reassessment.

Authors:  M H Gail
Journal:  Ann Intern Med       Date:  1972-05       Impact factor: 25.391

7.  Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.

Authors:  Pierluigi Tricoci; Yuliya Lokhnygina; Lisa G Berdan; Steven R Steinhubl; Dietrich C Gulba; Harvey D White; Neal S Kleiman; Philip E Aylward; Anatoly Langer; Robert M Califf; James J Ferguson; Elliott M Antman; L Kristin Newby; Robert A Harrington; Shaun G Goodman; Kenneth W Mahaffey
Journal:  Circulation       Date:  2007-11-19       Impact factor: 29.690

8.  Analysis of survival by tumor response.

Authors:  J R Anderson; K C Cain; R D Gelber
Journal:  J Clin Oncol       Date:  1983-11       Impact factor: 44.544

9.  Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer.

Authors:  Bryan P Schneider; Fengmin Zhao; Molin Wang; Vered Stearns; Silvana Martino; Vicky Jones; Edith A Perez; Tom Saphner; Antonio C Wolff; George W Sledge; William C Wood; Nancy E Davidson; Joseph A Sparano
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544

10.  Retrospective analysis of KRAS status in metastatic colorectal cancer patients: a single-center feasibility study.

Authors:  Jonathan Montomoli; Stephen Jacques Hamilton-Dutoit; Trine Frøslev; Aliki Taylor; Rune Erichsen
Journal:  Clin Exp Gastroenterol       Date:  2012-09-18
View more
  108 in total

1.  Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy.

Authors:  Andrew C Gordon; William J Gradishar; Virginia G Kaklamani; Avesh J Thuluvath; Robert K Ryu; Kent T Sato; Vanessa L Gates; Riad Salem; Robert J Lewandowski
Journal:  J Vasc Interv Radiol       Date:  2014-08-22       Impact factor: 3.464

2.  Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma and venous thrombus-Trends and effect on overall survival.

Authors:  Andrew T Lenis; Claire S Burton; Vishnukamal Golla; Aydin Pooli; Izak Faiena; David C Johnson; Amirali Salmasi; Alexandra Drakaki; Kiran Gollapudi; Jeremy Blumberg; Allan J Pantuck; Karim Chamie
Journal:  Urol Oncol       Date:  2019-03-28       Impact factor: 3.498

3.  Immortal person-time bias in the association between herpes zoster and survival following autologous stem cell transplantation.

Authors:  S A J Schmidt; T L Lash
Journal:  Bone Marrow Transplant       Date:  2015-03-30       Impact factor: 5.483

4.  Response to Di Cosimo, Torri, and Porcu.

Authors:  Elisabeth Trapp; Wolfgang Janni; Christian Schindlbeck; Julia Jückstock; Ulrich Andergassen; Amelie deGregorio; Marianna Alunni-Fabbroni; Marie Tzschaschel; Arkadius Polasik; Julian G Koch; Thomas W P Friedl; Peter A Fasching; Lothar Haeberle; Tanja Fehm; Andreas Schneeweiss; Matthias W Beckmann; Klaus Pantel; Volkmar Mueller; Brigitte Rack; Christoph Scholz
Journal:  J Natl Cancer Inst       Date:  2019-11-01       Impact factor: 13.506

5.  Precision tyrosine kinase inhibitor dosing in chronic myeloid leukemia?

Authors:  Giuseppe Saglio; Carmen Fava; Robert Peter Gale
Journal:  Haematologica       Date:  2019-05       Impact factor: 9.941

6.  [Safe pregnancy after breast cancer treatment in patients carrying BRCA mutations?]

Authors:  Rainer Souchon
Journal:  Strahlenther Onkol       Date:  2020-12-11       Impact factor: 3.621

7.  The search for surrogate endpoints for immunotherapy trials.

Authors:  Marc Buyse; Tomasz Burzykowski; Everardo D Saad
Journal:  Ann Transl Med       Date:  2018-06

8.  Overall survival in patients with residual disease after radical cystectomy and neoadjuvant chemotherapy.

Authors:  Izak Faiena; Amirali Salmasi; Neil Mendhiratta; Andrew T Lenis; Aydin Pooli; Alexandra Drakaki; Kiran Gollapudi; Jeremy Blumberg; Allan J Pantuck; Karim Chamie
Journal:  World J Urol       Date:  2018-05-11       Impact factor: 4.226

Review 9.  Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma.

Authors:  Jean-Luc Raoul; Joong-Won Park; Yoon-Koo Kang; Richard S Finn; Jun Suk Kim; Winnie Yeo; Blasé N Polite; Yee Chao; Ian Walters; Christine Baudelet; Riccardo Lencioni
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

Review 10.  Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer.

Authors:  Matteo Lambertini; Lucia Del Mastro; Giulia Viglietti; Noam F Pondé; Cinzia Solinas; Evandro de Azambuja
Journal:  Curr Treat Options Oncol       Date:  2017-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.